Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride

Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for cancer and autoimmune diseases, the companies announced Monday.
Lilly could pay more if Kelonia achieves specified clinical, re… [363 chars]